{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:07:08Z","timestamp":1793110028148,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jchf.2021.11.006","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T15:18:47Z","timestamp":1646061527000},"page":"184-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":157,"title":["Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction"],"prefix":"10.1016","volume":"10","author":[{"given":"Scott D.","family":"Solomon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"DeMets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Belohlavek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chern-En","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Jan","family":"Willem Borleffs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Comin-Colet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Dobreanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Drozdz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Antonio","family":"Alcocer Gamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Al Habeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Walter","family":"Cabrera Honorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan P.","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsvetana","family":"Katova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kitakaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bela","family":"Merkely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"O\u2019Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Francisco","family":"Kerr Saraiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey N.","family":"Tereschenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Thierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pham Nguyen","family":"Vinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrica","family":"Wilder\u00e4ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Zaozerska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lindholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Petersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2021.11.006_bib1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2021.11.006_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2021.11.006_bib3","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1161\/CIRCULATIONAHA.105.561423","article-title":"Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients","volume":"112","author":"Solomon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2021.11.006_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","article-title":"Heart failure with recovered left ventricular ejection fraction: JACC scientific expert panel","author":"Wilcox","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2021.11.006_bib5","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/CIRCULATIONAHA.113.006855","article-title":"Heart failure with recovered ejection fraction clinical description, biomarkers, and outcomes","volume":"129","author":"Basuray","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2021.11.006_bib6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.11.006_bib7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.11.006_bib8","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial","volume":"11","author":"Solomon","year":"2018","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.jchf.2021.11.006_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1388-9842(03)00052-7","article-title":"Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure \u2013 Assessment of Reduction in Mortality and morbidity (CHARM) program","volume":"5","author":"McMurray","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.11.006_bib10","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/ejhf.2064","article-title":"Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial","volume":"22","author":"Anker","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.11.006_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCHEARTFAILURE.112.972794","article-title":"Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial","volume":"6","author":"Shah","year":"2013","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.jchf.2021.11.006_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejheart.2007.12.010","article-title":"Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial","volume":"10","author":"McMurray","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.11.006_bib13","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.11.006_bib14","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1056\/NEJMc2112411","article-title":"Empagliflozin and major renal outcomes in heart failure","volume":"385","author":"Packer","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.11.006_bib15","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/ejhf.2065","article-title":"Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.11.006_bib16","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1016\/j.jacc.2021.04.070","article-title":"Classification of heart failure according to ejection fraction: JACC review topic of the week","author":"Lam","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"36","key":"10.1016\/j.jchf.2021.11.006_bib17","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2021.11.006_bib18","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.amjcard.2020.02.038","article-title":"Trends in\u00a0Treatment for Patients Hospitalized with Heart\u00a0Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart\u00a0Failure With an Aldosterone Antagonist (TOPCAT)","volume":"125","author":"Fudim","year":"2020","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.jchf.2021.11.006_bib19","first-page":"471","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2021.11.006_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2021.11.006_bib21","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium\u2013glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.jchf.2021.11.006_bib22","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2021.0939","article-title":"Quality of life in patients with heart failure with recovered ejection fraction","volume":"6","author":"Wohlfahrt","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2021.11.006_bib23","article-title":"Persistent recovery of normal left ventricular function and\u00a0dimension in idiopathic dilated cardiomyopathy during long-term follow-up: does real healing exist?","volume":"4","author":"Merlo","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.jchf.2021.11.006_bib24","article-title":"Global differences in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"14","author":"Tromp","year":"2021","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.jchf.2021.11.006_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ejhf.1227","article-title":"Heart failure with preserved ejection fraction in Asia","volume":"21","author":"Tromp","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2021.11.006_bib26","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1161\/CIRCULATIONAHA.120.052821","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart failure:\u00a0racial differences and a potential for reducing\u00a0disparities","author":"Morris","year":"2021","journal-title":"Circulation"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921005837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921005837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:00:23Z","timestamp":1761973223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177921005837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2213177921005837"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2021.11.006","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2021.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}